PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva
[Current Topics in Microbiology and Immunology] Phosphoinositide 3-kinase in Health and Disease Volume 347 || New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)
โ Scribed by Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K.
- Book ID
- 123615214
- Publisher
- Springer Berlin Heidelberg
- Year
- 2010
- Tongue
- German
- Weight
- 321 KB
- Edition
- 2011
- Category
- Article
- ISBN
- 3642148166
No coin nor oath required. For personal study only.
โฆ Synopsis
PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost invariably encounter roadblocks, often exposing unresolved questions in the basic understanding of the target
๐ SIMILAR VOLUMES
PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva
PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva